A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer

References

• Globocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. International Agency for research on Cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
   Google Scholar
• Diaz JP, Sonoda Y, Leitao MM, Zivanovic O, Brown CL, Chi DS, Barakat RR, Abu-Rustum NR. Oncologic outcome of fertility-sparing radical trachelectomy versus radical hysterectomy for stage IB1 cervical carcinoma. Gynecol Oncol 2008; 111:255–60; PMID:18755500; http://dx.doi.org/10.1016/j.ygyno.2008.07.014
   PubMed Web of Science ®Google Scholar
• Schmeler KM, Furmovitz M, Ramirez PT. Conservative management of early stage cervical cancer: is there a role for less radical surgery? Gynecol Oncol 2011; 120:321–5; PMID:21320670; http://dx.doi.org/10.1016/j.ygyno.2010.12.352
   PubMed Web of Science ®Google Scholar
• Dueñas-González A, Zarbá JJ, Patel F, Alcedo JC, Beslija S, Casanova L, Pattaranutaporn P, Hameed S, Blair JM, Barraclough H, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29:1678–85; PMID:21444871; http://dx.doi.org/10.1200/JCO.2009.25.9663
   PubMed Web of Science ®Google Scholar
• Petrelli F, De Stefani A, Raspagliesi F, Lorusso D, Barni S. Radiotherapy with concurrent cisplatin-based doublet or weekly cisplatin for cervical cancer: A systematic review and meta-analysis. Gynecol Oncol 2014; 134:166–71; PMID:24793000; http://dx.doi.org/10.1016/j.ygyno.2014.04.049
   PubMed Web of Science ®Google Scholar
• Höckel M, Horn LC, Einenkel J. Laterally extended endopelvic resection: surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy. Gynecol Oncol 2012; 127:297–302; PMID:22864112; http://dx.doi.org/10.1016/j.ygyno.2012.07.120
   PubMed Web of Science ®Google Scholar
• Qiu JT, Abdullah NA, Chou HH, Lin CT, Jung SM, Wang CC, Chen MY, Huang KG, Chang TC, Lai CH. Outcomes and prognosis of patients with recurrent cervical cancer after radical hysterectomy. Gynecol Oncol 2012; 127:472–7; PMID:22902919; http://dx.doi.org/10.1016/j.ygyno.2012.08.008
   PubMed Web of Science ®Google Scholar
• Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27:4649–55; PMID:19720909; http://dx.doi.org/10.1200/JCO.2009.21.8909
   PubMed Web of Science ®Google Scholar
• Cella D, Huang HQ, Monk BJ, Wenzel L, Benda J, McMeekin DS, Cohn D, Ramondetta L, Boardman CH. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010; 119:531–7; PMID:20837359; http://dx.doi.org/10.1016/j.ygyno.2010.08.020
   PubMed Web of Science ®Google Scholar
• Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014; 370:734–43; PMID:24552320; http://dx.doi.org/10.1056/NEJMoa1309748
   PubMed Web of Science ®Google Scholar
• Zighelboim I, Wright JD, Gao F, Case AS, Massad LS, Mutch DG, Powell MA, Thaker PH, Eisenhauer EL, Cohn DE, et al. Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent cervical cancer. Gynecol Oncol 2013; 130:64–8; PMID:23591400; http://dx.doi.org/10.1016/j.ygyno.2013.04.009
   PubMed Web of Science ®Google Scholar
• Soonthornthum T, Arias-Pulido H, Joste N, Lomo L, Muller C, Rutledge T, Verschraegen C. Epidermal growth factor receptor as biomarker for cervical cancer. Ann Oncol 2011; 22:2166–78; PMID:21325449; http://dx.doi.org/10.1093/annonc/mdq723
   PubMed Web of Science ®Google Scholar
• Dueñas-Gonzalez A, Cetina L, Coronel J, Cervantes-Madrid D. Emerging drugs for cervical cancer. Expert Opin Emerg Drugs 2012; 17:203–18; PMID:22530838; http://dx.doi.org/10.1517/14728214.2012.683409
   PubMed Web of Science ®Google Scholar
• Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther 2009; 9:1199–206; PMID:19624281; http://dx.doi.org/10.1517/14712590903110709
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002; 101:567–75; PMID:12237899; http://dx.doi.org/10.1002/ijc.10647
   PubMed Web of Science ®Google Scholar
• Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008; 98:749–55; PMID:18253126; http://dx.doi.org/10.1038/sj.bjc.6604222
   PubMed Web of Science ®Google Scholar
• Song H, Pan B, Yi J, Chen L. Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma. Exp Biol Med (Maywood) 2014; 239:529–41; PMID:24625442; http://dx.doi.org/10.1177/1535370214525315
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014; 3:e27048; PMID:24605265; http://dx.doi.org/10.4161/onci.27048
   PubMed Web of Science ®Google Scholar
• Crombet-Ramos Tania. Nimotuzumab: A humanized anti-EGFR antibody. Handbook of therapeutic antibodies. In: Dübel S, Reichert JM (ed). Taylor & Francis; 2014; 1679–94.
   Google Scholar
• Alberts DS, Blessing JA, Landrum LM, Warshal DP, Martin LP, Rose SL, Bonebrake AJ, Ramondetta LM. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol 2012; 127:451–5; PMID:22986144; http://dx.doi.org/10.1016/j.ygyno.2012.09.008
   PubMed Web of Science ®Google Scholar
• Lorusso D, Ferrandina G, Pignata S, Ludovisi M, Vigan∫ R, Scalone S, Scollo P, Breda E, Pietragalla A, Scambia G. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010; 21:61–6; PMID:19605508; http://dx.doi.org/10.1093/annonc/mdp266
   PubMed Web of Science ®Google Scholar
• Rose PG, Blessing JA, Lele S, Abulafia O. Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 102:210–3; PMID:16478630; http://dx.doi.org/10.1016/j.ygyno.2005.11.048
   PubMed Web of Science ®Google Scholar
• Candelaria M, Arias-Bonfill D, Chávez-Blanco A, Chanona J, Cantú D, Pérez C, Dueñas-González A. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer 2009; 19:1632–7; PMID:19955950; http://dx.doi.org/10.1111/IGC.0b013e3181a80bb5
   PubMed Web of Science ®Google Scholar
• Mackay HJ, Tinker A, Winquist E, Thomas G, Swenerton K, Oza A, Sederias J, Ivy P, Eisenhauer EA. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010; 116:163–7; PMID:19740535; http://dx.doi.org/10.1016/j.ygyno.2009.08.012
   PubMed Web of Science ®Google Scholar
• Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, MacKay H. Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199). Gynecol Oncol 2013; 130:269–74; PMID:23672928; http://dx.doi.org/10.1016/j.ygyno.2013.05.008
   PubMed Web of Science ®Google Scholar
• Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2009; 19:929–33; PMID:19574787; http://dx.doi.org/10.1111/IGC.0b013e3181a83467
   PubMed Web of Science ®Google Scholar
• Goncalves A, Fabbro M, Lhommé C, Gladieff L, Extra JM, Floquet A, Chaigneau L, Carrasco AT, Viens P. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecol Oncol 2008; 108:42–6; PMID:17980406; http://dx.doi.org/10.1016/j.ygyno.2007.07.057
   PubMed Web of Science ®Google Scholar
• Rodríguez MO, Rivero TC, del Castillo Bahi R, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodríguez E, Gracias E, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9:343–9; PMID:20448462; http://dx.doi.org/10.4161/cbt.9.5.10981
   PubMed Web of Science ®Google Scholar
• Rojo F, Gracias E, Villena N, Cruz T, Corominas JM, Corradino I, Cedeño M, Campas C, Osorio M, Iznaga N, et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010; 16:2474–82; PMID:20371675; http://dx.doi.org/10.1158/1078-0432.CCR-09-3042
   PubMed Web of Science ®Google Scholar
• Basavaraj C, Sierra P, Shivu J, Melarkode R, Montero E, Nair P. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. Cancer Biol Ther 2010; 10:673–81; PMID:20647773; http://dx.doi.org/10.4161/cbt.10.7.12793
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs 2012; 30:1138–43; PMID:21170759; http://dx.doi.org/10.1007/s10637-010-9619-8
   PubMed Web of Science ®Google Scholar
• Boland W, Bebb G. The emerging role of nimotuzumab in the treatment of non-small cell lung cancer. Biologics 2010; 4:289–98; PMID:21116327
   PubMedGoogle Scholar
• Massimino M, Bode U, Biassoni V, Fleischhack G. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011; 11:247–56; PMID:21171927; http://dx.doi.org/10.1517/14712598.2011.546341
   PubMed Web of Science ®Google Scholar
• Ramos TC, Figueredo J, Catala M, González S, Selva JC, Cruz TM, Toledo C, Silva S, Pestano Y, Ramos M, et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: Report from a phase I/II trial. Cancer Biol Ther 2006; 5:375–9; PMID:16575203; http://dx.doi.org/10.4161/cbt.5.4.2522
   PubMed Web of Science ®Google Scholar
• Cabanas R, Saurez G, Alert J, Reyes A, Valdes J, Gonzalez MC, Pedrayes JL, Valle L, Infante M, Avila M, et al. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility. Cancer Biother Radiopharm 2014; 29:173–8; PMID:24784755; http://dx.doi.org/10.1089/cbr.2013.1591
   PubMed Web of Science ®Google Scholar
• Hertlein L, Lenhard M, Kirschenhofer A, Kahlert S, Mayr D, Burges A, Friese K. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients. Arch Gynecol Obstet 2011; 283:109–13; PMID:20180130; http://dx.doi.org/10.1007/s00404-010-1389-1
   PubMed Web of Science ®Google Scholar
• Santin AD, Sill MW, McMeekin DS, Leitao MM Jr, Brown J, Sutton GP, Van Le L, Griffin P, Boardman CH. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2011; 122:495–500; PMID:21684583; http://dx.doi.org/10.1016/j.ygyno.2011.05.040
   PubMed Web of Science ®Google Scholar
• Bebb G, Boland W, Melosky B. Dont´t jump to rash conclusions. Cancer Biol Ther 2011;11:639–41; PMID:21304273; http://dx.doi.org/10.4161/cbt.11.7.14920
   PubMed Web of Science ®Google Scholar
• Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfo E, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22:1646–54; PMID:15117987; http://dx.doi.org/10.1200/JCO.2004.03.089
   PubMed Web of Science ®Google Scholar
• Akashi Y, Okamoto I, Iwasa T, Yoshida T, Suzuki M, Hatashita E, Yamada Y, Satoh T, Fukuoka M, Ono K, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanized monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer 2008; 98:749–55; PMID:18253126; http://dx.doi.org/10.1038/sj.bjc.6604222
   PubMed Web of Science ®Google Scholar
• Garrido G, Tikhomirov IA, Rabasa A, Yang E, Gracia E, Iznaga N, Fernández LE, Crombet T, Kerbel RS, Pérez R. Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile. Cancer Biol Ther 2011; 11:373–82; PMID:21150278; http://dx.doi.org/10.4161/cbt.11.4.14097
   PubMed Web of Science ®Google Scholar